Jenburkt Pharmaceuticals Ltd vs Kobo Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Jenburkt Pharmaceuticals Ltd is ₹ 1044 as of 30 Apr 15:30 . The P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 11.1 on March 2021 to 13.9 on March 2025 . This represents a CAGR of 4.60% over 5 yearsThe P/E Ratio of Kobo Biotech Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 182.84 crore on March 2021 to ₹ 446.49 crore on March 2025 . This represents a CAGR of 19.55% over 5 yearsThe Market Cap of Kobo Biotech Ltd changed from ₹ 17.63 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 44.84 crore as compare to the Sep '25 revenue of ₹ 47.64 crore. This represent the decline of -5.88% The revenue of Kobo Biotech Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 9.24 crore as compare to the Sep '25 ebitda of ₹ 15.18 crore. This represent the decline of -39.13% The ebitda of Kobo Biotech Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 7.42 crore to ₹ 5.93 crore over 7 quarters. This represents a CAGR of -12.02% The net profit of Kobo Biotech Ltd changed from ₹ -1.33 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 yearsThe Dividend Payout of Kobo Biotech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

About Kobo Biotech Ltd

Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992.
Effective 19th October, 2020, the Company's name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited.
The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US.

FAQs for the comparison of Jenburkt Pharmaceuticals Ltd and Kobo Biotech Ltd

Which company has a larger market capitalization, Jenburkt Pharmaceuticals Ltd or Kobo Biotech Ltd?

Market cap of Jenburkt Pharmaceuticals Ltd is 460 Cr while Market cap of Kobo Biotech Ltd is 6 Cr

What are the key factors driving the stock performance of Jenburkt Pharmaceuticals Ltd and Kobo Biotech Ltd?

The stock performance of Jenburkt Pharmaceuticals Ltd and Kobo Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jenburkt Pharmaceuticals Ltd and Kobo Biotech Ltd?

As of May 4, 2026, the Jenburkt Pharmaceuticals Ltd stock price is INR ₹1044.25. On the other hand, Kobo Biotech Ltd stock price is INR ₹2.85.

How do dividend payouts of Jenburkt Pharmaceuticals Ltd and Kobo Biotech Ltd compare?

To compare the dividend payouts of Jenburkt Pharmaceuticals Ltd and Kobo Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.